Audeo Oncology (Audeo Oncology) Interest Coverage : No Debt ⁽¹⁾ (As of Sep. 2012)

View and export this data going back to . Start your Free Trial

What is Audeo Oncology Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Audeo Oncology's Operating Income for the three months ended in Sep. 2012 was $-4.81 Mil. Audeo Oncology's Interest Expense for the three months ended in Sep. 2012 was $0.00 Mil. Audeo Oncology has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Audeo Oncology's Interest Coverage or its related term are showing as below:

AURX's Interest Coverage is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 12.175
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Audeo Oncology Interest Coverage Historical Data

The historical data trend for Audeo Oncology's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Audeo Oncology Interest Coverage Chart

Audeo Oncology Annual Data

Trend

Jun10

Jun11

Jun12

Interest Coverage

No Debt

Audeo Oncology Quarterly Data
	Jun11	Mar12	Jun12	Sep12
Interest Coverage	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Audeo Oncology's Interest Coverage

For the Drug Manufacturers - General subindustry, Audeo Oncology's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Audeo Oncology's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's Interest Coverage falls into.

Audeo Oncology Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Audeo Oncology's Interest Coverage for the fiscal year that ended in Jun. 2012 is calculated as

Here, for the fiscal year that ended in Jun. 2012, Audeo Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-9.48 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Audeo Oncology had no debt ⁽¹⁾.

Audeo Oncology's Interest Coverage for the quarter that ended in Sep. 2012 is calculated as

Here, for the three months ended in Sep. 2012, Audeo Oncology's Interest Expense was $0.00 Mil. Its Operating Income was $-4.81 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Audeo Oncology had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

Audeo Oncology (DELISTED:AURX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Audeo Oncology Interest Coverage Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Audeo Oncology (Audeo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » Interest Coverage

Traded in Other Exchanges

N/A

Address

Website

http://www.audeooncology.com

Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.